Opthea taps investors to raise almost $230 million to fund late-stage trials

June 12, 2024 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

The Australian company led by former Novartis Australia head and Medicines Australia board member Fred Guerard is seeking to raise over $220 million to support its late-stage clinical trials. …

Subscribe now to continue reading.

Latest Video

The lesson to learn from the Guild is that you cannot defeat what you do not know
December 14, 2025 - Latest News
Lilly announces Phase 3 results for triple agonist in obesity and knee osteoarthritis
December 15, 2025 - Latest News
Algorae unveils major breakthrough in AI-driven drug combination discovery
December 14, 2025 - Australian Biotech
GBMA to host inaugural summit aimed at addressing medicine shortages
December 15, 2025 - Latest News
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - Latest News

Opthea taps investors to raise almost $230 million to fund late-stage trials

This is a preview of subscriber content

Latest Video

Most Read

The lesson to learn from the Guild is that you cannot defeat what you do not know

Lilly announces Phase 3 results for triple agonist in obesity and knee osteoarthritis

Algorae unveils major breakthrough in AI-driven drug combination discovery

GBMA to host inaugural summit aimed at addressing medicine shortages

The industry is probably right to resist, it just needs to prepare for the response

New Stories

The industry is probably right to resist, it just needs to prepare for the response

Cynata completes patient enrolment in Phase 2 trial for aGvHD therapy

Prescient secures European approval to launch PTX-100 trial for rare lymphoma

Orthocell lodges European and UK regulatory application for Remplir

Neuren wins second FDA approval for trofinetide with launch of formulation

Dimerix completes adult recruitment in Phase 3 trial for FSGS treatment DMX-200

Radiopharm Theranostics reports high success rate in Phase 2b imaging trial

Sign In

Opthea taps investors to raise almost $230 million to fund late-stage trials

This is a preview of subscriber content

Latest Video

Most Read

The lesson to learn from the Guild is that you cannot defeat what you do not know

Lilly announces Phase 3 results for triple agonist in obesity and knee osteoarthritis

Algorae unveils major breakthrough in AI-driven drug combination discovery

GBMA to host inaugural summit aimed at addressing medicine shortages

The industry is probably right to resist, it just needs to prepare for the response

Follow Us

New Stories

The industry is probably right to resist, it just needs to prepare for the response

Cynata completes patient enrolment in Phase 2 trial for aGvHD therapy

Prescient secures European approval to launch PTX-100 trial for rare lymphoma

Orthocell lodges European and UK regulatory application for Remplir

Neuren wins second FDA approval for trofinetide with launch of formulation

Dimerix completes adult recruitment in Phase 3 trial for FSGS treatment DMX-200

Radiopharm Theranostics reports high success rate in Phase 2b imaging trial